Found: 16
Select item for more details and to access through your institution.
A novel ARH splice site mutation in a Mexican kindred with autosomal recessive hypercholesterolemia.
- Published in:
- Human Genetics, 2005, v. 116, n. 1/2, p. 114, doi. 10.1007/s00439-004-1192-9
- By:
- Publication type:
- Article
Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection.
- Published in:
- JAMA: Journal of the American Medical Association, 2014, v. 312, n. 4, p. 353, doi. 10.1001/jama.2014.7734
- By:
- Publication type:
- Article
A Loss-of-Function Splice Acceptor Variant in Is Protective for Type 2 Diabetes.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Contribution of Common Genetic Variation to the Risk of Type 2 Diabetes in the Mexican Mestizo Population.
- Published in:
- Diabetes, 2012, v. 61, n. 12, p. 3314, doi. 10.2337/db11-0550
- By:
- Publication type:
- Article
Combined loss of CDH1 and downstream regulatory sequences drive early-onset diffuse gastric cancer and increase penetrance of hereditary diffuse gastric cancer.
- Published in:
- Gastric Cancer, 2023, v. 26, n. 5, p. 653, doi. 10.1007/s10120-023-01395-0
- By:
- Publication type:
- Article
Episensitization: defying time's arrow.
- Published in:
- Frontiers in Oncology, 2015, p. 1, doi. 10.3389/fonc.2015.00134
- By:
- Publication type:
- Article
Peginterferon α-2a Plus Ribavirin in Latino and Non-Latino Whites With HCV Genotype 1: Histologic Outcomes and Tolerability From the LATINO Study.
- Published in:
- American Journal of Gastroenterology (Springer Nature), 2010, v. 105, n. 10, p. 2177, doi. 10.1038/ajg.2010.157
- By:
- Publication type:
- Article
Genome-wide association study of colorectal cancer in Hispanics.
- Published in:
- Carcinogenesis, 2016, v. 37, n. 6, p. 547, doi. 10.1093/carcin/bgw046
- By:
- Publication type:
- Article
Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.
- Published in:
- Annals of Hepatology: Official Journal of the Mexican Association of Hepatology, 2016, v. 15, n. 6, p. 834, doi. 10.5604/16652681.1222098
- By:
- Publication type:
- Article
A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV.
- Published in:
- Annals of Hepatology: Official Journal of the Mexican Association of Hepatology, 2014, v. 13, n. 4, p. 364, doi. 10.1016/s1665-2681(19)30843-9
- By:
- Publication type:
- Article
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
- Published in:
- Liver International, 2016, v. 36, n. 2, p. 189, doi. 10.1111/liv.12964
- By:
- Publication type:
- Article
In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions.
- Published in:
- Liver International, 2014, v. 34, n. 7, p. e217, doi. 10.1111/liv.12352
- By:
- Publication type:
- Article
A Double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects
- Published in:
- Liver International, 2014, v. 34, n. 6, p. e89, doi. 10.1111/liv.12334
- By:
- Publication type:
- Article
Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon α-2a (40KD) (PEGASYS<sup>®</sup>) plus ribavirin (COPEGUS<sup>®</sup>) for 16 or 24 weeks.
- Published in:
- Liver International, 2009, v. 29, n. 2, p. 237, doi. 10.1111/j.1478-3231.2008.01859.x
- By:
- Publication type:
- Article
Weight affect relapse rates in latinos with genotype 2/3 chronic hepatitis C (CHC) treated with peg IFN alfa-2a (Pegasys) 180 mcg/week and 800 mg daily of ribavirin for 24 weeks.
- Published in:
- Journal of Medical Virology, 2008, v. 80, n. 9, p. 1576, doi. 10.1002/jmv.21253
- By:
- Publication type:
- Article
Interferon γ–Induced Protein10 Kinetics in Treatment-Naive Versus Treatment-Experienced Patients Receiving Interferon-Free Therapy for Hepatitis C Virus Infection: Implications for the Innate Immune Response.
- Published in:
- Journal of Infectious Diseases, 2014, v. 210, n. 12, p. 1881, doi. 10.1093/infdis/jiu325
- By:
- Publication type:
- Article